Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Deffered Revenue: 2022-2024

Historic Non-Current Deffered Revenue for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $5.4 million.

  • Immunocore Holdings' Non-Current Deffered Revenue fell 13.83% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 13.83%. This contributed to the annual value of $5.4 million for FY2024, which is 1.47% down from last year.
  • Immunocore Holdings' Non-Current Deffered Revenue amounted to $5.4 million in FY2024, which was down 1.47% from $5.5 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' Non-Current Deffered Revenue registered a high of $5.5 million during FY2023, and its lowest value of $5.2 million during FY2022.
  • Over the past 3 years, Immunocore Holdings' median Non-Current Deffered Revenue value was $5.4 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first climbed by 5.21% in 2023, then decreased by 1.47% in 2024.
  • Yearly analysis of 3 years shows Immunocore Holdings' Non-Current Deffered Revenue stood at $5.2 million in 2022, then climbed by 5.21% to $5.5 million in 2023, then declined by 1.47% to $5.4 million in 2024.